Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Overview of the results of recent beta blocker trials
Autore:
Tendera, M; Ochala, A;
Indirizzi:
Silesian Sch Med, Dept Cardiol 3, PL-40635 Katowice, Poland Silesian Sch Med Katowice Poland PL-40635 l 3, PL-40635 Katowice, Poland
Titolo Testata:
CURRENT OPINION IN CARDIOLOGY
fascicolo: 3, volume: 16, anno: 2001,
pagine: 180 - 185
SICI:
0268-4705(200105)16:3<180:OOTROR>2.0.ZU;2-7
Fonte:
ISI
Lingua:
ENG
Soggetto:
CHRONIC HEART-FAILURE; RANDOMIZED INTERVENTION TRIAL; ADRENERGIC-RECEPTOR BLOCKADE; LEFT-VENTRICULAR DYSFUNCTION; DOUBLE-BLIND; CONGESTIVE CARDIOMYOPATHY; MYOCARDIAL-INFARCTION; MERIT-HF; CARVEDILOL; METOPROLOL;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
47
Recensione:
Indirizzi per estratti:
Indirizzo: Tendera, M Silesian Sch Med, Dept Cardiol 3, Ziolowa St 47, PL-40635 Katowice, Poland Silesian Sch Med Ziolowa St 47 Katowice Poland PL-40635 Poland
Citazione:
M. Tendera e A. Ochala, "Overview of the results of recent beta blocker trials", CURR OPIN C, 16(3), 2001, pp. 180-185

Abstract

Results of the studies published or reported within the last 2 years provide convincing evidence that beta-blockers can decrease mortality in patients with chronic symptomatic heart failure because of left ventricular systolic dysfunction. The Cardiac Insufficiency Bisoprolol Study (CIBIS)-II and Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) trials showed a 34% reduction in all-cause death with bisoprolol and metoprolol therapy in patients with class II-III heart failure. Data from Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS), witha 35% mortality reduction, extended this benefit to class IV patients treated with carvedilol who do not require intravenous diuretics or positive inotropes. Ongoing beta-blocker studies address new topics, such as treatmentof older patients, in whom diastolic heart failure may be more common, anddirect comparison of different drugs. Although the use of beta-blockers for heart failure tends to increase, implementation of the knowledge from thetrials in clinical practice still remains a challenge. (C) 2001 LippincottWilliams & Wilkins, Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 31/03/20 alle ore 08:52:31